Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 5/20 | 0.48 |
| ▸ | F2 | P00734 | 7/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3914502 | 0.99 | CAPN1 (0.48) | CAPN1F2MMP1MMP13ADAM17 | |
| SCHEMBL3912360 | 0.86 | CAPN1 (0.55) | CAPN1F2MMP1MMP13ADAM17 | |
| SCHEMBL3909187 | 0.82 | CTSL (0.47) | F2MMP1ADAM17 | |
| SCHEMBL6987411 | 0.77 | F2 (0.56) | F2 | |
| SCHEMBL1771259 | 0.76 | MMP1 (0.62) | MMP1MMP13ADAM17 | |
| SCHEMBL7064055 | 0.76 | USP2 (0.62) | F2MMP1MMP13ADAM17 | |
| SCHEMBL516960 | 0.76 | KMT2A (0.52) | CAPN1F2CTSBNPY5R | |
| SCHEMBL7790058 | 0.75 | POLB (0.58) | CAPN1F2NPY5R | |
| SCHEMBL7790060 | 0.75 | POLB (0.58) | CAPN1F2NPY5R | |
| SCHEMBL7787807 | 0.74 | ALDH1A1 (0.56) | CAPN1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572833-B2 | Drug composition comprising dipeptidyl aldehyde derivative | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-11 | — | — | US | disclosed |
| US-7052714-B1 | Ophthalmic adhesive preparations for percutaneous adsorption | SENJU PHARMACEUTICAL CO., LTD (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20040048929-A1 | Drug composition comprising dipeptidyl aldehyde derivative | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1334718-A1 | DRUG COMPOSITION COMPRISING DIPEPTYDYL ALDEHYDE DERIVATIVE | Senju Pharmaceutical Co., Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-1221315-A1 | OPHTHALMIC ADHESIVE PREPARATIONS FOR PERCUTANEOUS ABSORPTION | Senju Pharmaceutical Co., Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048929-A1 | Drug composition comprising dipeptidyl aldehyde derivative | DPP4, DPP3, DPP7 | CAPN1 2707/4885F2 4322/4885MMP1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.